Q2 2026 revenue was flat year-over-year, but adjusted EBITDA and EPS declined sharply. Free cash flow improved significantly, and guidance for 2026 was raised for revenue, EBITDA, and cash flow. New facility openings and Medicaid policy changes remain key factors.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.